Managers / Q1 2024 · view latest →
Foresite Capital Management IV, LLC
CIK 0001704132 · 9200 W. SUNSET BOULEVARD, SUITE 515, WEST HOLLYWOOD, CA, 90069 · 415-877-4887
Summary
Foresite Capital Management IV, LLC reported $198M in U.S.-listed holdings across 5 positions for Q1 2024.
The portfolio is heavily concentrated: Pharvaris N V alone accounts for 47.2% of reported value.
The book was largely unchanged from Q4 2023.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 56.5% · $112M
- Common Stock · 43.5% · $86M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| Pharvaris N.V. | HELD | +0 | 4.04M | −$20M | $93M |
| KURAKura Oncology, Inc. | HELD | +0 | 1.85M | +$13M | $39M |
| Kinnate Biopharma Inc. | HELD | +0 | 9.67M | +$3M | $26M |
| Lyell Immunopharma, Inc. | HELD | +0 | 8.32M | +$2M | $19M |
| SNDXSyndax Pharmaceuticals, Inc. | HELD | +0 | 875.0K | +$2M | $21M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | Pharvaris N.V. | COM | 47.16% | $93M | 4.04M |
| 2 | KURAKura Oncology, Inc.history → | COM | 19.94% | $39M | 1.85M |
| 3 | Kinnate Biopharma Inc. | COM | 13.00% | $26M | 9.67M |
| 4 | SNDXSyndax Pharmaceuticals, Inc.history → | COM | 10.52% | $21M | 875.0K |
| 5 | Lyell Immunopharma, Inc. | COM | 9.38% | $19M | 8.32M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $237M | 8 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $230M | 7 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $183M | 6 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $124M | 6 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $111M | 5 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $109M | 4 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $153M | 5 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $149M | 4 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $198M | 5 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $198M | 5 | Feb 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $180M | 7 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $203M | 7 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $193M | 8 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $234M | 8 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $311M | 8 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $371M | 8 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $357M | 9 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $486M | 9 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $679M | 12 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $740M | 13 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $835M | 13 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $921M | 13 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $443M | 15 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $205M | 12 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $81M | 11 | May 28, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2019 | $232M | 14 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $309M | 19 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $354M | 22 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $278M | 16 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.